Wednesday, November 19, 2025 A randomized Phase II trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) brachytherapy as monotherapy in localized prostate cancer: analysis of initial arms of Canadian cancer trials group PR19Low Dose-Rate Brachytherapy (LDR) and High Dose-Rate Brachytherapy (HDR) are options for favorable risk prostate cancer. Researchers hypothesized that HDR provides comparable disease control with less urinary toxicity. Primary objective was to determine prostate cancer control at 48 months, defined as a PSA < 0.4 ng/ml.Morton G, Vigneault E, Barkati M, Helou J, Niazi TM, Robinson J, Loblaw DA, Tseng CL, Chung HT, Delouya G, Menard C, Martin AG, Chung P, Batchelar D, Brundage MD, Whelan K, Ding K, Parulekar W. A randomized Phase II trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) brachytherapy as monotherapy in localized prostate cancer: analysis of initial arms of Canadian cancer trials group PR19 (NCT02960087). Radiotherapy and Oncology 212: 111124. 2025. https://doi.org/10.1016/j.radonc.2025.111124
